Crispr Therapeutics options imply 8.9% move in share price post-earnings
PremiumThe FlyCrispr Therapeutics options imply 8.9% move in share price post-earnings
5d ago
CRSP Earnings this Week: How Will it Perform?
Premium
Pre-Earnings
CRSP Earnings this Week: How Will it Perform?
13d ago
Cathie Wood Trims Tesla Stake, Shifts Focus to This Lesser-Known Stock
Premium
Market News
Cathie Wood Trims Tesla Stake, Shifts Focus to This Lesser-Known Stock
15d ago
Pfizer withdrawal of Oxbryta raises questions, sends Fulcrum stock higher
PremiumThe FlyPfizer withdrawal of Oxbryta raises questions, sends Fulcrum stock higher
1M ago
Leerink sees little impact to genetic medicines from Pfizer’s Oxbryta withdrawal
Premium
The Fly
Leerink sees little impact to genetic medicines from Pfizer’s Oxbryta withdrawal
1M ago
Disc Medicine appoints Caffe as CRO
Premium
The Fly
Disc Medicine appoints Caffe as CRO
2M ago
Mid-Cap Stocks: CRSP Offers Tremendous Growth Potential With Inherent Risks
PremiumMarket NewsMid-Cap Stocks: CRSP Offers Tremendous Growth Potential With Inherent Risks
3M ago
Crispr Therapeutics price target lowered to $60 from $66 at RBC Capital
Premium
The Fly
Crispr Therapeutics price target lowered to $60 from $66 at RBC Capital
3M ago
Crispr Therapeutics price target lowered to $59 from $60 at Stifel
Premium
The Fly
Crispr Therapeutics price target lowered to $59 from $60 at Stifel
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100